Search Results - "Ugarenko, Michal"

Uncoupling histone H3K4 trimethylation from developmental gene expression via an equilibrium of COMPASS, Polycomb and DNA methylation by Douillet, Delphine, Sze, Christie C., Ryan, Caila, Piunti, Andrea, Shah, Avani P., Ugarenko, Michal, Marshall, Stacy A., Rendleman, Emily J., Zha, Didi, Helmin, Kathryn A., Zhao, Zibo, Cao, Kaixiang, Morgan, Marc A., Singer, Benjamin D., Bartom, Elizabeth T., Smith, Edwin R., Shilatifard, Ali

“…The COMPASS protein family catalyzes histone H3 Lys 4 (H3K4) methylation and its members are essential for regulating gene expression. MLL2/COMPASS methylates…”
Get full text

PAF1 regulation of promoter-proximal pause release via enhancer activation by Chen, Fei Xavier, Xie, Peng, Collings, Clayton K., Cao, Kaixiang, Aoi, Yuki, Marshall, Stacy A., Rendleman, Emily J., Ugarenko, Michal, Ozark, Patrick A., Zhang, Anda, Shiekhattar, Ramin, Smith, Edwin R., Zhang, Michael Q., Shilatifard, Ali

“…Gene expression in metazoans is regulated by RNA polymerase II (Pol II) promoter-proximal pausing and its release. Previously,we showed that Pol II–associated…”
Get full text

Coordinated regulation of cellular identity-associated H3K4me3 breadth by the COMPASS family by Sze, Christie C, Ozark, Patrick A, Cao, Kaixiang, Ugarenko, Michal, Das, Siddhartha, Wang, Lu, Marshall, Stacy A, Rendleman, Emily J, Ryan, Caila A, Zha, Didi, Douillet, Delphine, Chen, Fei Xavier, Shilatifard, Ali

“…Set1A and Set1B, two members of the COMPASS family of methyltransferases that methylate the histone H3 lysine 4 (H3K4) residue, have been accredited as primary…”
Get full text

Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent by Cutts, Suzanne M, Rephaeli, Ada, Nudelman, Abraham, Ugarenko, Michal, Phillips, Don R

“…Doxorubicin has been in use as a key anticancer drug for forty years, either as a single agent or in combination chemotherapy. It functions primarily by…”
Get more information

DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation by Cao, Kaixiang, Ugarenko, Michal, Ozark, Patrick A., Wang, Juan, Marshall, Stacy A., Rendleman, Emily J., Liang, Kaiwei, Wang, Lu, Zou, Lihua, Smith, Edwin R., Yue, Feng, Shilatifard, Ali

“…Actively transcribed genes in mammals are decorated by H3K79 methylation, which is correlated with transcription levels and is catalyzed by the histone…”
Get full text

Abstract B46: CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb Repressive complex 2 via a H3K27M-like mechanism by Piunti, Andrea, Smith, Edwin, Morgan, Marc, Ugarenko, Michal, Khaltyan, Natalia, Helmin, Kathryn, Ryan, Caila, Murray, David, Rickels, Ryan, Yilmaz, Bahar, Rendleman, Emily, Savas, Jeffrey, Singer, Benjamin, Bulun, Serdar, Shilatifard, Ali

“…Abstract Dysregulation of Polycomb Repressive Complex 2 (PRC2) function is a common feature of many cancer types, including both solid and hematologic…”
Get full text

CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism by Piunti, Andrea, Smith, Edwin R, Morgan, Marc A J, Ugarenko, Michal, Khaltyan, Natalia, Helmin, Kathryn A, Ryan, Caila A, Murray, David C, Rickels, Ryan A, Yilmaz, Bahar D, Rendleman, Emily J, Savas, Jeffrey N, Singer, Benjamin D, Bulun, Serdar E, Shilatifard, Ali

“…Using biochemical characterization of fusion proteins associated with endometrial stromal sarcoma, we identified JAZF1 as a new subunit of the NuA4…”
Get full text

Abstract A29: Bcl-2 overexpression provides short-term resistance to doxorubicin-DNA adducts but does not protect against longer-term treatments in HL-60 cells by Ugarenko, Michal, Rephaeli, Ada, Nudelman, Abraham, Koch, Tad H., Phillips, Don R., Cutts, Suzanne M.

“…Abstract The anthracycline anticancer agent doxorubicin functions primarily as a topoisomerase II inhibitor but forms more cytotoxic DNA adducts in the…”
Get full text

ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin–DNA adducts by Ugarenko, Michal, Nudelman, Abraham, Rephaeli, Ada, Kimura, Ken-Ichi, Phillips, Don R., Cutts, Suzanne M.

“…Bcl-2 overexpressing HL-60 cells are resistant to doxorubicin–DNA adduct forming treatments. The addition of the Bcl-2 inhibitor ABT-737 was able to overcome…”
Get full text

Development of pluronic micelle-encapsulated doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapy by Ugarenko, Michal, Chan, Chee-Kai, Nudelman, Abraham, Rephaeli, Ada, Cutts, Suzanne M, Phillips, Don R

“…The chemotherapeutic agent doxorubicin forms drug-DNA adducts that are enhanced by formaldehyde-releasing prodrugs such as AN-9. One of the major limitations…”
Get more information